Related Experiment Video
Updated: Jun 12, 2026
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
Published on: May 16, 2012
MicroRNAs and prostate cancer
Yingxin Pang1, Charles Y F Young, Huiqing Yuan
1Institute of Biochemistry and Molecular Biology, Shandong University, Jinan, China.
Abstract:
MicroRNAs (miRNAs) are a class of small, non-coding, single-stranded RNAs that negatively regulate gene expression by mainly binding to 30 untranslated region (UTR) of target mRNAs at the post-transcriptional level. Recent studies have demonstrated that aberrant expressions of miRNAs are closely associated with the development, invasion, metastasis and prognosis of various cancers including prostate cancer (PCa). The proposed molecular mechanisms that underlie the aberrant expression of miRNAs result from gene changes, epigenetic modification and alteration of Dicer abundance. Although up to 50 miRNAs have been reported to be significantly expressed in human PCa, only a small number of them were experimentally shown to make contribution to the pathogenesis of PCa. The aim of this review is to describe the mechanisms of several known miRNAs, summarize recent studies on the relevance of altered expression of oncogenic miRNAs (e.g. miR-221/-222, miR-21, and miR-125b) and tumor suppressor miRNAs (e.g. miR-101, miR-126*, miR-146a, miR-330, miR-34 cluster, and miR-200 family) for PCa. Additionally, their potential clinical applications and prospects in PCa, such as biomarkers and clinical therapies, are also briefly discussed.
Insights
MicroRNAs (miRNAs) regulate gene expression and are linked to prostate cancer (PCa) development. This review details specific miRNAs involved in PCa pathogenesis and their potential as biomarkers and therapeutic targets.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression post-transcriptionally.
- Aberrant miRNA expression is implicated in the development, invasion, metastasis, and prognosis of cancers, including prostate cancer (PCa).
- Mechanisms for altered miRNA expression involve gene changes, epigenetic modifications, and Dicer abundance variations.
Purpose of the Study:
- To review the mechanisms of known miRNAs in prostate cancer.
- To summarize recent findings on oncogenic and tumor suppressor miRNAs in PCa.
- To discuss the clinical potential of miRNAs as biomarkers and therapeutic targets for PCa.
Main Methods:
- Literature review of studies on miRNA expression and function in prostate cancer.
- Analysis of experimental evidence linking specific miRNAs to PCa pathogenesis.
- Synthesis of information on clinical applications of miRNAs in PCa.
Main Results:
- Numerous miRNAs show altered expression in PCa, with a subset experimentally validated for pathogenic roles.
- Specific oncogenic miRNAs (e.g., miR-221/-222, miR-21, miR-125b) and tumor suppressor miRNAs (e.g., miR-101, miR-200 family) are highlighted.
- MiRNAs show promise as diagnostic biomarkers and therapeutic agents for PCa.
Conclusions:
- Understanding miRNA mechanisms is crucial for PCa research.
- Targeting specific miRNAs offers potential for novel PCa diagnostics and therapeutics.
- Further research is needed to fully translate miRNA potential into clinical practice for PCa.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
01:22MicroRNAs
02:23Abnormal Proliferation